Jim Simons’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $319M | Buy |
2,418,897
+180,100
| +8% | +$23.9M | 0.5% | 19 |
|
|
2025
Q4 | $318M | Sell |
2,238,797
-179,500
| -7% | -$26M | 0.49% | 28 |
|
|
2025
Q3 | $339M | Buy |
2,418,297
+51,900
| +2% | +$7.03M | 0.45% | 29 |
|
|
2025
Q2 | $297M | Sell |
2,366,397
-136,300
| -5% | -$15.6M | 0.4% | 34 |
|
|
2025
Q1 | $277M | Buy |
2,502,697
+13,300
| +0.5% | +$1.68M | 0.42% | 29 |
|
|
2024
Q4 | $340M | Sell |
2,489,397
-85,149
| -3% | -$10.5M | 0.5% | 25 |
|
|
2024
Q3 | $297M | Buy |
2,574,546
+106,400
| +4% | +$14.6M | 0.45% | 24 |
|
|
2024
Q2 | $340M | Buy |
2,468,146
+216,500
| +10% | +$29.7M | 0.58% | 16 |
|
|
2024
Q1 | $311M | Buy |
2,251,646
+263,100
| +13% | +$35.9M | 0.49% | 23 |
|
|
2023
Q4 | $262M | Buy |
1,988,546
+398,382
| +25% | +$45.9M | 0.41% | 39 |
|
|
2023
Q3 | $179M | Sell |
1,590,164
-53,238
| -3% | -$5.61M | 0.31% | 58 |
|
|
2023
Q2 | $155M | Sell |
1,643,402
-303,662
| -16% | -$29.7M | 0.22% | 84 |
|
|
2023
Q1 | $197M | Buy |
1,947,064
+333,400
| +21% | +$34.7M | 0.26% | 69 |
|
|
2022
Q4 | $193M | Buy |
1,613,664
+171,200
| +12% | +$20.1M | 0.26% | 71 |
|
|
2022
Q3 | $153M | Sell |
1,442,464
-6,559
| -0.5% | -$666K | 0.22% | 99 |
|
|
2022
Q2 | $141M | Buy |
1,449,023
+168,900
| +13% | +$15.6M | 0.17% | 123 |
|
|
2022
Q1 | $120M | Sell |
1,280,123
-143,541
| -10% | -$12.2M | 0.14% | 143 |
|
|
2021
Q4 | $121M | Buy |
1,423,664
+67,700
| +5% | +$6.23M | 0.15% | 144 |
|
|
2021
Q3 | $130M | Buy |
1,355,964
+113,241
| +9% | +$10.7M | 0.17% | 117 |
|
|
2021
Q2 | $121M | Sell |
1,242,723
-155,141
| -11% | -$14.9M | 0.15% | 131 |
|
|
2021
Q1 | $136M | Sell |
1,397,864
-409,327
| -23% | -$42.9M | 0.17% | 114 |
|
|
2020
Q4 | $173M | Sell |
1,807,191
-342,273
| -16% | -$33.1M | 0.19% | 101 |
|
|
2020
Q3 | $207M | Buy |
2,149,464
+664,700
| +45% | +$76.9M | 0.21% | 83 |
|
|
2020
Q2 | $181M | Buy |
1,484,764
+765,382
| +106% | +$84.6M | 0.16% | 126 |
|
|
2020
Q1 | $62.3M | Sell |
719,382
-19,790
| -3% | -$1.94M | 0.06% | 322 |
|
|
2019
Q4 | $79.5M | Buy |
739,172
+735,272
| +18,853% | +$77M | 0.06% | 360 |
|
|
2019
Q3 | $351K | Sell |
3,900
-11,341
| -74% | -$1.06M | ﹤0.01% | 2989 |
|
|
2019
Q2 | $1.29M | Sell |
15,241
-212,700
| -93% | -$17.5M | ﹤0.01% | 2572 |
|
|
2019
Q1 | $20.1M | Buy |
227,941
+152,100
| +201% | +$12.7M | 0.02% | 962 |
|
|
2018
Q4 | $5.42M | Buy |
+75,841
| New | +$7.27M | 0.01% | 1675 |
|
|
2018
Q2 | – | Sell |
-162,341
| Closed | -$13.5M | – | 3440 |
|
|
2018
Q1 | $13.5M | Sell |
162,341
-224,900
| -58% | -$19M | 0.01% | 1184 |
|
|
2017
Q4 | $30M | Buy |
+387,241
| New | +$26.4M | 0.03% | 692 |
|
|
2015
Q4 | – | Sell |
-130,641
| Closed | -$5.2M | – | 3375 |
|
|
2015
Q3 | $5.2M | Buy |
+130,641
| New | +$6.31M | 0.01% | 1371 |
|
Other funds holding NBIX
VPM
VCM
Jim Simons's NBIX Position: Q1 2026 in Review
Jim Simons increased its Neurocrine Biosciences (NBIX) stake by 8% in Q1 2026, buying an estimated $23.9M and bringing the position to 2,418,897 shares worth $319M. The position accounts for 0.5% of the portfolio, ranked #19.
Jim Simons first reported a position in NBIX in Q3 2015 and has held it in 33 quarters since. The position peaked at $340M in Q4 2024. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Jim Simons held 2,418,897 shares of Neurocrine Biosciences worth $319M as of Q1 2026.
- Jim Simons bought 180,100 Neurocrine Biosciences shares in Q1 2026, an estimated $23.9M.
- Neurocrine Biosciences made up 0.5% of Jim Simons's portfolio in Q1 2026, its #19 holding.
- Jim Simons first reported a position in Neurocrine Biosciences in Q3 2015 and has held it in 33 quarters since.
- Jim Simons's Neurocrine Biosciences position peaked at $340M in Q4 2024.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.